The Mayor’s Charity
Councillor Robert Freeman
Charity Dinner at Boodle's
Charity Dinner at Brooks's
A Reception with Emily Maitlis speaking on the US Presidential Election
The Royal Marsden and Royal Brompton hospitals are working closely together on research that aims to improve the diagnosis and treatment of complex lung cancers.
Headlines in the national press have recently highlighted exciting new developments in immunotherapy that can be used in the treatment of cancer. Ways are being found to bolster a patient's own immune system so that it can recognise tumours that it wasn't previously recognising and then react to destroy them.
The Mayor's fundraising is supporting research being carried out jointly by The Royal Marsden and Royal Brompton, in collaboration with expertise at the Institute of Cancer Research and Imperial College, London. It aims to develop quicker and more effective tests to predict which lung cancer patients will benefit from new treatments.
This work is some of the most advanced in the world and has the potential to be transformational in the care of lung cancer patients.
Facts about Lung Cancer
Lung Cancer is the second most common cancer, accounting for 43,000 cases per year in the UK, the vast majority of whom die within one year of diagnosis.
It is the most common cause of death from cancer; more deaths than breast, colon and prostate cancer combined. For women it is the biggest killer, accounting for 20% of all cancer deaths.
Lung cancer does not discriminate and many lung cancer patients have never smoked.
If lung cancer in people who had never smoked was in its own category of cancer, it would rank in the top ten cancers globally.